ASH News Daily 2016 - Issue 3 - A-18

monday 2016
Page A-18

ASH News Daily

Monday, December 5, 2016

ASH Live: Today's Remote Session Viewing Schedule
ASH Central, Sails Pavilion
7 - 8:30 a.m.

10:30 a.m. - 12 p.m.

2:45 - 4:15 p.m.

4:30 - 6 p.m.

711. Cell Collection and Processing:
Graft Mobilization, Manipulation,
and Characterization

502. Hematopoiesis: Regulation
of Gene Transcription, Cytokines,
Signal Transduction, Apoptosis and
Cell Cycle Regulation I

721. Clinical Allogeneic
Transplantation: Conditioning
Regimens, Engraftment, and
Acute Transplant Toxicities:
Post-Transplant Complications

502. Hematopoiesis:
Regulation of Gene
Transcription, Cytokines, Signal
Transduction, Apoptosis and Cell
Cycle Regulation III

721. Clinical Allogeneic Transplantation: Conditioning Regimens,
Engraftment, and Acute Transplant
Toxicities: Conditioning Regimens

701. Experimental Transplantation:
Basic Biology, Pre-Clinical Models:
GVHD and GVL; Mechanisms

723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease
Recurrence: Biological And Clinical
Risk Assessment In Transplantation

652. Myeloma: Pathophysiology
and Pre-Clinical Studies,
excluding Therapy: Targeting
Tumor Microenvironment and
Drug Resistance in Myeloma

722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Pathobiology
and Enhancing Immunity

723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease
Recurrence: Survivorship and Late
Effects After Transplantation

731. Clinical Autologous Transplantation: Results: Clinical Autologous
Transplantation in Myeloma II

732. Clinical Allogeneic
Transplantation: Results:
Transplant Access and
Development of Risk
Scores for HCT Outcomes

731. Clinical Autologous Transplantation: Results: Clinical Autologous
Transplantation in Myeloma I

902. Health Services Research -
Malignant conditions: Racial and
Ethnic Disparities in Outcomes

901. Health Services Research -
Non-malignant conditions: Transfusion Practices and Bleeding

901. Health Services Research -
Non-malignant conditions:
Thromboembolism and
Anticoagulation

Channel 5

732. Clinical Allogeneic
Transplantation: Results:
Conditioning Regimen, Donor
Source, and Long-Term Outcomes
Among Allogeneic HCT Recipients

651. Myeloma: Biology and
Pathophysiology, excluding
Therapy: Genetic Alterations/
Profiling and Clonal Evolution of
Multiple Myeloma

653. Myeloma: Therapy, excluding
Transplantation: Novel Approaches

653. Myeloma: Therapy, excluding
Transplantation: IMiD/Proteasome
Inhibitor Combinations and
Maintenance Therapy

Channel 6

904. Outcomes Research -
Malignant Conditions:
Survivorship and Late Effects

732. Clinical Allogeneic
Transplantation: Results:
Reducing Relapse

615. Acute Myeloid Leukemia: Commercially available Therapy, excluding Transplantation: APL and other
AML Specific Subsets

603. Oncogenes and Tumor
Suppressors: Altered Epigenetic
and Metabolic Regulation

Channel 7

612. Acute Lymphoblastic
Leukemia: Clinical Studies:
Molecular Features, Toxicity
of Therapy, and New Approaches
to Immunotherapy

508. Bone Marrow Failure:
Molecular & Clinical Advances
in AAA & Stress Induced
Marrow Dysfunction

616. Acute Myeloid Leukemia:
Novel Therapy, excluding
Transplantation: Clinical Trials
Of Novel Drugs And
Combinations In AML

615. Acute Myeloid Leukemia:
Commercially available Therapy,
excluding Transplantation:
Epigenetic Modifiers and New
Combinations for the Tratment
of AML

Channel 8

613. Acute Myeloid Leukemia:
Clinical Studies: New Drugs for
Older AML

612. Acute Lymphoblastic
Leukemia: Clinical Studies: New
Approaches to Treatment
Stratification and MRD Utilization

618. Acute Lymphoblastic
Leukemia: Biology, Cytogenetics
and Molecular Markers in
Diagnosis and Prognosis: ALL
Biology and Targets for Therapy

616. Acute Myeloid Leukemia:
Novel Therapy, excluding
Transplantation: FLT3 and IDH
Targeted Therapies In AML

617. Acute Myeloid Leukemia:
Biology, Cytogenetics and Molecular
Markers in Diagnosis and Prognosis:
Insights Into AML Based On
Comprehensive Sequencing Data

616. Acute Myeloid Leukemia:
Novel Therapy, excluding Transplantation: Emerging Immune-Based
Therapies For AML

631. Chronic Myeloid Leukemia:
Biology and Pathophysiology,
excluding Therapy: CML Stem Cells
and the Niche

617. Acute Myeloid Leukemia:
Biology, Cytogenetics and
Molecular Markers in Diagnosis
and Prognosis: Advances In
Understanding The
Pathophysiology Of AML

Channel 10

618. Acute Lymphoblastic
Leukemia: Biology, Cytogenetics
and Molecular Markers in Diagnosis
and Prognosis: Relapsed ALL and
Therapy Resistance?

632. Chronic Myeloid Leukemia:
Therapy: TKI-Discontinuation

632. Chronic Myeloid
Leukemia: Therapy:
TKI-Optimization And Switching

618. Acute Lymphoblastic
Leukemia: Biology, Cytogenetics
and Molecular Markers in
Diagnosis and Prognosis:
Genetic Risk Factors in ALL

Channel 11

632. Chronic Myeloid Leukemia:
Therapy: Progress With Therapy

635. Myeloproliferative Syndromes:
Basic Science: Cooperating Genes
& Epigenetics

634. Myeloproliferative Syndromes:
Clinical: Clinical and Molecular
Correlative Studies

631. Chronic Myeloid Leukemia:
Biology and Pathophysiology,
excluding Therapy: Novel
Targets in CML Biology

Channel 12

635. Myeloproliferative Syndromes:
Basic Science: Translational Studies

617. Acute Myeloid Leukemia:
Biology, Cytogenetics and Molecular
Markers in Diagnosis and Prognosis:
New Insights into AML Biology and
Therapeutic Targeting

635. Myeloproliferative Syndromes:
Basic Science: Stem Cells &
Microenvironment

634. Myeloproliferative
Syndromes: Clinical: Clinical
Trials with JAK inhibitors

Channel 1

Channel 2

Channel 3

Channel 4

Channel 9

Table of Contents for the Digital Edition of ASH News Daily 2016 - Issue 3